b3c0ffda-f298-45dd-b494-191788cb7013
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.380
- G2M_CHECKPOINT+0.320
- E2F_TARGETS+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
- MYC_TARGETS_V1+0.180
- MITOTIC_SPINDLE+0.140
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.130
- UNFOLDED_PROTEIN_RESPONSE+0.050
- NOTCH_SIGNALING+0.020
- SPERMATOGENESIS+0.000
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.470
- INTERFERON_ALPHA_RESPONSE-0.470
- INTERFERON_GAMMA_RESPONSE-0.470
- ALLOGRAFT_REJECTION-0.440
- ANDROGEN_RESPONSE-0.440
- IL6_JAK_STAT3_SIGNALING-0.400
- COMPLEMENT-0.390
- PANCREAS_BETA_CELLS-0.370
- CHOLESTEROL_HOMEOSTASIS-0.340
- FATTY_ACID_METABOLISM-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-98-A53A-01A-11R-A262-07 | — | cohortSQ1 | 0.898 |
| 2 | ERR2208946 | — | — | 0.897 |
| 3 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.891 |
| 4 | BS_VAAHBH60 | Supratentorial Ependymoma | — | 0.888 |
| 5 | BS_9V633J1X | medulloblastoma | — | 0.883 |
| 6 | TCGA-E2-A158-01A-11R-A12D-07 | — | E | 0.880 |
| 7 | SRR8518301 | — | E | 0.880 |
| 8 | MDT-AP-0396 | Med | Medulloblastoma | 0.875 |
| 9 | BS_D0RDN4K5 | Embryonal tumors | — | 0.872 |
| 10 | SJEPD030942_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |